drugset / Trial / NCT06832228
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
NaSingle-groupOpen-labelTreatment
Summary
This study aims to observe and explore the efficacy and safety of pomalidomide combination with rituximab and Anti-PD-1 Antibody in Third or Later Line Therapy of diffuse large B-cell lymphoma (DLBCL)
Timeline
- Start
- 2024-09-01
- Primary completion
- 2025-09-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pomalidomide | Other / unclassified | 4 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |